Market Authorization Testing for Drugs: The Qualitative Foundation of the Authorization Process
The development of a drug involves years of research and development, as well as preclinical and clinical trials. But even after all this work is complete, there is still one final and crucial phase before the drug can be brought to market: the . In this process, the data on quality, safety, and efficacy submitted to regulatory authorities must be complete, verifiable, and in accordance with international standards.
The tests conducted prior to the market launch of drugs form the basis of the quality section of this document. These tests, which are required in Turkey by the TİTCK (Turkish Medicines and Medical Devices Agency), in Europe by the EMA (European Medicines Agency), and in the U.S. by the FDA (Food and Drug Administration), demonstrate the identity, purity, potency, stability, and biological activity of the drug. Conducting these tests in accordance with the principles of GLP (Good Laboratory Practice) and GMP (Good Manufacturing Practice) is mandatory for the approval of the marketing authorization application.
The Common Technical Dossier (CTD) in the Approval Process
Marketing authorization applications for drugs are prepared in the CTD (Common Technical Document) format as part of international harmonization efforts. The CTD consists of five modules, with quality data included in Module 3 (Quality). The marketing authorization tests constitute the content of this module:
- Module 1: Administrative Information and Regional Requirements
- Module 2: Summaries on Quality, Safety, and Efficacy (QOS, Nonclinical, Clinical)
- Module 3: Quality (chemical, pharmaceutical, and biological data)
- Module 4: Reports on Preclinical Studies
- Module 5: Clinical Trial Reports
The test data submitted as part of Module 3 must be prepared separately for the active pharmaceutical ingredient (API) and the finished drug product. This data must comply with the ICH guidelines (Q1–Q14).
Main Categories of Market Authorization Tests
The tests required for the approval of a drug can be divided into the following main categories:
1. Identity and Purity Tests
They demonstrate that the drug product contains the specified active ingredient and that it meets an acceptable level of purity. They are conducted in accordance with ICH Guidelines Q3A, Q3B, Q3C, and Q3D.
- Identity: Confirmation of the active pharmaceutical ingredient (API) using FTIR, HPLC, and NMR
- Contamination Profile: Organic contaminants, solvent residues, heavy metals
- Enantiomeric Purity: Ratio of optical isomers determined by chiral HPLC
2. Wage Determination and Wage Equality
Verification of the product's active ingredient content and consistency among individual doses.
- Assay (Content Determination): Determination of API content using HPLC
- Content Uniformity: In accordance with the requirements of the Pharmacopoeia
- Dissolution Rate: For Solid Oral Dosage Forms
3. Stability Studies (ICH Q1)
Proof that the product maintains its quality throughout its entire shelf life.
- Long-term stability: 25 °C/60% relative humidity or 30 °C/65% relative humidity
- Accelerated stability: 40 °C/75% relative humidity
- Intermediate stability: 30 °C/65% relative humidity
- Light stability: ICH Q1B-compliant light exposure
4. Bioavailability and Bioequivalence (ICH M13A)
Demonstrates the equivalence of generic drugs to the reference drug.
- Validation of Bioanalytical Methods: Plasma Analysis Using LC-MS/MS
- Pharmacokinetic parameters: Cmax, AUC, Tmax
- Statistical equivalence: 80–125% criterion with a 90% confidence interval
5. Microbiological Quality Tests
These tests are performed on sterile products and products for which microbiological limits are specified.
- Sterility Test: Compliant with the Pharmacopoeia
- Testing for Microbiological Limits: TAMC, TYMC, and Detection of Pathogens
- Endotoxin Test: LAL Method
Summary of Tests for Market Launch and Related Guidelines
The following table summarizes the basic tests required as part of the drug approval process and the corresponding ICH guidelines:
| Test Category | Related ICH Guideline | Evaluated Parameter | CTD Module |
|---|---|---|---|
| Identity and Purity | ICH Q3A, Q3B, Q3C, Q3D, Q6A | Identity of the active ingredient, impurity profile, heavy metals | Module 3.2.S |
| Quantitative Determination | ICH Q2(R2), Q6A | API Content, Content Uniformity, Solubility | Module 3.2.P |
| Stability | ICH Q1A(R2), Q1B, Q1E | Shelf life, degradation profile, light stability | Module 3.2.S.7 / 3.2.P.8 |
| Bioequivalence | ICH M13A, E6(R2) | Cmax, AUC, Tmax, statistical equivalence | Module 5.3.1 |
| Microbiological Quality | I Q6A, Q4B | Sterility, microbiological limits, endotoxins | Module 3.2.P.3 |
| Analytical Validation | ICH Q2(R2), Q14 | Trueness, Accuracy, Specificity, LOD/LOQ | Module 3.2.S.4 / 3.2.P.5 |
The Role of GLP and GMP in the Approval Process
The validity of market authorization tests depends not only on the use of correct analytical methods, but also on these tests being conducted in accredited laboratories and in accordance with GLP principles. GLP establishes strict rules in areas such as staff training, equipment calibration, standard operating procedures (SOPs), data integrity, and audit trails.
Similarly, GMP compliance of the manufacturing process is an integral part of the marketing authorization application. Compliance with both GLP and GMP demonstrates that the drug maintains consistent quality at both the laboratory and production scales.
GLP-compliant solutions for market authorization testing with Nano-Test
The regulatory approval process for pharmaceutical manufacturers requires extensive data preparation and meticulous analytical work. Nano-Test is a GLP-accredited solution partner that offers all the quality testing required for this process under one roof.
Nano-Test – Statement of Work
Nano-Test performs all quality tests required for the drug launch process in its GLP- and ISO/IEC 17025-accredited laboratories. Our service portfolio:
- Identity and Purity Testing: API verification and the development of impurity profiles using FTIR, HPLC-DAD, LC-MS/MS, GC-MS/MS, and ICP-MS.
- Quantitative Determination and Uniformity of Assay: Assay, uniformity of assay, and dissolution tests in accordance with the monographs of the pharmacopoeias.
- Stability testing: Long-term, accelerated, and interim stability studies in accordance with ICH Q1A(R2); photostability testing in accordance with ICH Q1B.
- Bioanalytics and Bioequivalence: Analysis of plasma samples using LC-MS/MS, calculation of pharmacokinetic parameters, and statistical evaluation of bioequivalence.
- Microbiological Quality: Sterility tests, tests to determine microbial limits, endotoxin tests (LAL), and tests to assess the efficacy of preservatives.
- Analytical Validation: Method development, validation, and transfer in accordance with ICH Q2(R2) and Q14.
All of our work is presented in the form of reports in CTD format. Data integrity (ALCOA+ principles) is ensured and is acceptable during inspections by regulatory authorities. GLP compliance reports are prepared.
Advantages of Nano-Test for Market Launch Testing:
- A one-stop solution: All identity, purity, stability, bioanalytical, and microbiological testing under one roof.
- CTD-compliant reporting: Reports that meet the requirements of Module 3 and Module 5 and are accepted by regulatory authorities.
- Compliance with current regulations: Immediate adaptation to newly published guidelines such as ICH Q14.
- State-of-the-art technological infrastructure: LC-MS/MS, GC-MS/MS, ICP-MS, HPLC-DAD, and climate chambers.
- Specialized Staff: A team with experience in the fields of pharmaceutical analysis, bioanalysis, validation, and regulatory approval.
- Fast Reporting: Results are delivered within 5–10 business days for standard analyses.
The market launch of drugs requires the successful completion of a comprehensive and thorough testing process. Identity, purity, strength, stability, bioequivalence, and microbiological quality tests provide scientific evidence of the drug’s safety, efficacy, and quality. Conducting these tests in accredited laboratories in accordance with GLP principles, as well as providing complete reporting in the CTD format, are prerequisites for the acceptance of your marketing authorization application.
With its GLP-accredited infrastructure, advanced analytical technologies, and expert staff, Nano-Test fully meets the requirements of pharmaceutical manufacturers for regulatory testing. Partner with Nano-Test to expedite your regulatory submission and meet the requirements of regulatory authorities.